Logo image of VERV

VERVE THERAPEUTICS INC (VERV) Stock Fundamental Analysis

NASDAQ:VERV - Nasdaq - US92539P1012 - Common Stock - Currency: USD

11.28  +0.07 (+0.62%)

After market: 11.2415 -0.04 (-0.34%)

Fundamental Rating

3

Overall VERV gets a fundamental rating of 3 out of 10. We evaluated VERV against 555 industry peers in the Biotechnology industry. While VERV has a great health rating, there are worries on its profitability. VERV is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

VERV had negative earnings in the past year.
VERV had a negative operating cash flow in the past year.
In the past 5 years VERV always reported negative net income.
VERV had a negative operating cash flow in each of the past 5 years.
VERV Yearly Net Income VS EBIT VS OCF VS FCFVERV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

VERV's Return On Assets of -29.47% is fine compared to the rest of the industry. VERV outperforms 67.39% of its industry peers.
With a decent Return On Equity value of -38.23%, VERV is doing good in the industry, outperforming 71.53% of the companies in the same industry.
Industry RankSector Rank
ROA -29.47%
ROE -38.23%
ROIC N/A
ROA(3y)-26.82%
ROA(5y)-34.01%
ROE(3y)-34.07%
ROE(5y)-42.09%
ROIC(3y)N/A
ROIC(5y)N/A
VERV Yearly ROA, ROE, ROICVERV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

VERV does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VERV Yearly Profit, Operating, Gross MarginsVERV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K

More info and screens

7

2. Health

2.1 Basic Checks

VERV does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VERV has been increased compared to 1 year ago.
Compared to 5 years ago, VERV has more shares outstanding
There is no outstanding debt for VERV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
VERV Yearly Shares OutstandingVERV Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
VERV Yearly Total Debt VS Total AssetsVERV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

VERV has an Altman-Z score of 2.40. This is not the best score and indicates that VERV is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of VERV (2.40) is better than 70.99% of its industry peers.
VERV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.4
ROIC/WACCN/A
WACC8.99%
VERV Yearly LT Debt VS Equity VS FCFVERV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

VERV has a Current Ratio of 9.84. This indicates that VERV is financially healthy and has no problem in meeting its short term obligations.
VERV has a better Current ratio (9.84) than 78.02% of its industry peers.
A Quick Ratio of 9.84 indicates that VERV has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 9.84, VERV is in the better half of the industry, outperforming 78.20% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.84
Quick Ratio 9.84
VERV Yearly Current Assets VS Current LiabilitesVERV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

2

3. Growth

3.1 Past

VERV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 26.48%, which is quite impressive.
The Revenue has grown by 271.44% in the past year. This is a very strong growth!
EPS 1Y (TTM)26.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.68%
Revenue 1Y (TTM)271.44%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%479.03%

3.2 Future

VERV is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -6.55% yearly.
Based on estimates for the next years, VERV will show a small growth in Revenue. The Revenue will grow by 0.88% on average per year.
EPS Next Y-6.15%
EPS Next 2Y-10.49%
EPS Next 3Y-3.78%
EPS Next 5Y-6.55%
Revenue Next Year70.15%
Revenue Next 2Y-26.34%
Revenue Next 3Y-16.91%
Revenue Next 5Y0.88%

3.3 Evolution

VERV Yearly Revenue VS EstimatesVERV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
VERV Yearly EPS VS EstimatesVERV Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VERV. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VERV. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VERV Price Earnings VS Forward Price EarningsVERV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VERV Per share dataVERV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

A cheap valuation may be justified as VERV's earnings are expected to decrease with -3.78% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.49%
EPS Next 3Y-3.78%

More info and screens

0

5. Dividend

5.1 Amount

VERV does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VERVE THERAPEUTICS INC

NASDAQ:VERV (7/3/2025, 8:15:44 PM)

After market: 11.2415 -0.04 (-0.34%)

11.28

+0.07 (+0.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14/bmo
Earnings (Next)N/A N/A
Inst Owners94.32%
Inst Owner Change4.32%
Ins Owners5.16%
Ins Owner Change0.57%
Market Cap1.01B
Analysts83.75
Price Target14.37 (27.39%)
Short Float %21.31%
Short Ratio3.58
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.98%
Min EPS beat(2)18.3%
Max EPS beat(2)47.66%
EPS beat(4)4
Avg EPS beat(4)24.6%
Min EPS beat(4)15.43%
Max EPS beat(4)47.66%
EPS beat(8)8
Avg EPS beat(8)20.65%
EPS beat(12)9
Avg EPS beat(12)11.75%
EPS beat(16)10
Avg EPS beat(16)-68.84%
Revenue beat(2)2
Avg Revenue beat(2)234.22%
Min Revenue beat(2)223.6%
Max Revenue beat(2)244.83%
Revenue beat(4)4
Avg Revenue beat(4)195.33%
Min Revenue beat(4)139.53%
Max Revenue beat(4)244.83%
Revenue beat(8)8
Avg Revenue beat(8)209.59%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-44.04%
PT rev (3m)-38%
EPS NQ rev (1m)0.36%
EPS NQ rev (3m)-0.12%
EPS NY rev (1m)3.67%
EPS NY rev (3m)10.7%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-22.7%
Revenue NY rev (1m)20.31%
Revenue NY rev (3m)138.74%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 16.87
P/FCF N/A
P/OCF N/A
P/B 2.12
P/tB 2.12
EV/EBITDA N/A
EPS(TTM)-2.11
EYN/A
EPS(NY)-2.87
Fwd EYN/A
FCF(TTM)-1.65
FCFYN/A
OCF(TTM)-1.6
OCFYN/A
SpS0.67
BVpS5.31
TBVpS5.31
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -29.47%
ROE -38.23%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-26.82%
ROA(5y)-34.01%
ROE(3y)-34.07%
ROE(5y)-42.09%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 66.21%
Cap/Sales 7.59%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.84
Quick Ratio 9.84
Altman-Z 2.4
F-Score4
WACC8.99%
ROIC/WACCN/A
Cap/Depr(3y)232.67%
Cap/Depr(5y)247.65%
Cap/Sales(3y)257.49%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.68%
EPS Next Y-6.15%
EPS Next 2Y-10.49%
EPS Next 3Y-3.78%
EPS Next 5Y-6.55%
Revenue 1Y (TTM)271.44%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%479.03%
Revenue Next Year70.15%
Revenue Next 2Y-26.34%
Revenue Next 3Y-16.91%
Revenue Next 5Y0.88%
EBIT growth 1Y5.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-13.17%
EBIT Next 3Y-16.21%
EBIT Next 5YN/A
FCF growth 1Y3.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.29%
OCF growth 3YN/A
OCF growth 5YN/A